Artivion (NYSE:AORT) Given New $32.00 Price Target at Needham & Company LLC

Artivion (NYSE:AORT) had its target price trimmed by Needham & Company LLC from $34.00 to $32.00 in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other analysts also recently commented on the company. Oppenheimer upped their price objective on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. JMP Securities restated a “market outperform” rating and set a $33.00 price target on shares of Artivion in a research note on Tuesday, December 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $31.40.

Artivion Stock Down 9.1 %

AORT opened at $25.33 on Tuesday. Artivion has a 12 month low of $18.38 and a 12 month high of $32.33. The business has a 50-day moving average of $29.75 and a two-hundred day moving average of $27.83. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -1,266.25 and a beta of 1.75.

Artivion (NYSE:AORT) last released its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $97.31 million during the quarter, compared to analysts’ expectations of $100.82 million. On average, research analysts expect that Artivion will post 0.37 earnings per share for the current year.

Insider Activity

In related news, SVP Jean F. Holloway sold 8,070 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total transaction of $243,068.40. Following the transaction, the senior vice president now directly owns 153,862 shares of the company’s stock, valued at approximately $4,634,323.44. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Amy Horton sold 4,329 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the sale, the chief accounting officer now directly owns 135,660 shares of the company’s stock, valued at $4,023,675.60. This trade represents a 3.09 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,017 shares of company stock valued at $600,007. Company insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Quarry LP lifted its holdings in Artivion by 210.8% in the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after buying an additional 820 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Artivion by 236.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after acquiring an additional 786 shares during the last quarter. R Squared Ltd acquired a new position in shares of Artivion in the fourth quarter worth about $39,000. Arcadia Investment Management Corp MI purchased a new position in Artivion in the fourth quarter valued at about $43,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Artivion during the 4th quarter valued at approximately $64,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.